What are the benefits of oral delivery of insulin and how can algae support candidate therapeutic proteins?

By Jane Byrne contact

- Last updated on GMT

© GettyImages/da-kuk
© GettyImages/da-kuk

Related tags: Oramed, Oral insulin, spirulina, C. difficile, Drug delivery

These are some of the questions we will be asking leading experts next week.

Significant R&D interest exists in developing less invasive or non-invasive routes for the systemic delivery of biologics, including subcutaneous, transdermal, oral, inhalation, nasal and buccal routes.

An online BioPharma-Reporter webinar, live on May 19, will look at innovative delivery around proteins and other biologics.

Don’t miss out. Register now ​for the event: Delivery Systems for Biologics.

Game changing technology

Our panel comprises two accomplished experts who are going to tell us about potentially game changing technology.

Dr Roy Eldor, scientific advisor to Oramed Pharmaceuticals, and currently director of the Diabetes Unit at the Institute of Endocrinology, Metabolism & Hypertension, Tel-Aviv Sourasky Medical Center, will talk about the clinical development to date of Oramed’s oral insulin candidate, ORMD-0801, which is lining up to be the world’s first insulin pill.

He will also outline the proprietary drug delivery platform supporting that capsule, and the benefits of oral delivery of insulin.

Oramed announced earlier this month that it has enrolled 100% of the patients in a Phase 3 study of ORMD-0801 under FDA approved protocols.

Also speaking in our webinar​ is Mark Heinnickel, principal scientist, Lumen Bioscience. He will provide insights into that Seattle-based company’s efforts to optimize therapeutic protein production in spirulina, and how such a platform is providing a way to rapidly produce mass quantities of biologic drugs for common diseases that currently lack effective treatments.

Lumen recently produced a paper summarizing preclinical and early-stage clinical testing of its orally delivered spirulina-expressed antibody targeting campylobacter. The technology is also said to offer promising treatment options for conditions such as C. difficile​, inflammatory bowel disease, and certain metabolic diseases,

Want to know more​? Tune in next week: the webinar is live at 10am Chicago time and at 5pm in Paris.

Related topics: Bio Developments

Related news

Show more